Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03445533 · ClinicalTrials.gov registry record · Phase 3
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
A Phase 3 study, sponsored by Idera Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 481
- Enrollment target
NCT03445533 is a Phase 3 study that was terminated before completion, run by Idera Pharmaceuticals. The registered enrollment target is 481 participants.
The verdict
NCT03445533, a Phase 3 study, was terminated before completion, sponsored by Idera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 481 participants
- Enrollment target
Study Summary
A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
Interventions
- DRUG Ipilimumab
- DRUG Tilsotolimod with Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2018-05-30 |
| Est. Completion | 2021-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03445533
The ClinicalTrials.gov registry entry for NCT03445533 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 481 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idera Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT03445533 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03445533 about?
NCT03445533 is a clinical study titled "A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma". A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced melanoma
What is the current status of trial NCT03445533?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 481 participants. The study started on 2018-05-30. Estimated completion is 2021-06-01.
What interventions are being tested in trial NCT03445533?
The interventions under investigation include: Ipilimumab (DRUG), Tilsotolimod with Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03445533?
This trial is sponsored by Idera Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.